Fundraising

For Fundraising enquires please contact Anna on 020 7487 3892, email anna@cureparkinsons.org.uk or write to us at

120, Baker Street
London
W1U 6TU

Latest

Alpha-synuclein oligomers: a new hope

A report part funded by The Cure Parkinson's Trust assesses the evidence for the toxicity and prion-like activity of oligomeric forms of alpha-synuclein and discusses the advances in our understanding of the role of alpha-synuclein in Parkinson’s and current approaches being taken to therapeutically target alpha-synuclein oligomers and their implications.
The Association of Pesticide Use and Parkinson's

Researchers assessed the influence of occupational pesticide use on the prevalence of Parkinson's Disease in people with information available concerning occupational, residential, and household sources of pesticide exposure.
The Psigma Foundation's Newcastle to Edinburgh Cycle Challenge

Raising over £2000, staff from Psigma’s Scottish office took on the amazing cycle challenge from Newcastle to Edinburgh covering 167 miles over two days in support of The Cure Parkinson’s Trust. Read their story here.
Breaking News: Diabetes Drug Shows Potential as Disease-Modifying Therapy for Parkinson’s

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

Related

Most read

Breakthrough in stem cell treatment for Parkinson's

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.
Tom Isaacs

We are devastated to announce that Tom Isaacs, President and Co-founder of The Cure Parkinson’s Trust (CPT) died on Wednesday morning (31st May). Tom’s passing was unexpected and swift.
New Evidence Suggests Parkinson's Might Not Start in The Brain

A new study adds to a raft of new evidence which suggests Parkinson's starts in the gut.
Trials - Repurposed drugs

Our Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop, or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.
Are Stem Cell-Based Therapies for Parkinson’s Disease Ready for the Clinic?

A research paper published in the Journal of Parkinson's Disease (Spring 2016) discusses an impending clinical trial in Parkinson's disease (PD) using parthenogenetic stem cells.
Our story
Apply for Funding
Study links Parkinson's disease to Gut Bacteria

A new study finds that people with Parkinson's disease appear to have distinctly different gut bacteria.
The NAC Trial - the facts
CPT Co founder Tom Isaacs featured in the Journal of Parkinson's Disease

Tag cloud

Alex Flynn alpha synuclein codicil Cure diagnostic direct debit flowers fundraising GDNF Leicestershire Country Cricket mitochondrial function parkinsons Parkinson's placebo present Sense Park

Tom's Top Tips for Living Well with Parkinson's

Tom Isaacs and David Sangster - Advocacy & Teamwork

Parkinson's Movement

People with Parkinson's and Linked Clinical Trials

People with Parkinson's talk about the importance of clinical trials. Read more

Our 2017 Annual Review

Find out more about our fantastic achievements over the year... Read more